Browsing Tag

Apellis Pharmaceuticals

SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 30…

James Pereira Jul 30, 2023

SYFOVRE reduced nonsubfoveal GA lesion growth by up to 45% between Months 24-30 compared to projected sham in the GALE…
Read More...

James Pereira May 6, 2023

<!--…
Read More...

James Pereira Apr 24, 2023

<!--…
Read More...

James Pereira Mar 7, 2023

<!--…
Read More...

James Pereira Feb 18, 2023

A Media Snippet accompanying this announcement is available by clicking on the image or link below: Stay connected…
Read More...

James Pereira Dec 16, 2022

WALTHAM, Mass., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global…
Read More...

James Pereira Nov 23, 2022

WALTHAM, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global…
Read More...

James Pereira Nov 8, 2022

Plans to submit 24-month Phase 3 data to the FDA for intravitreal pegcetacoplan for geographic atrophy (GA); expected…
Read More...

James Pereira Nov 1, 2022

WALTHAM, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global…
Read More...

James Pereira Oct 1, 2022

New analyses of microperimetry data showed positive trends with both monthly and every-other-month pegcetacoplan…
Read More...